|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
These observations are consistent with the nuclear co-localization of the AR and beta-Catenin shown by immunohistochemistry in human prostate cancer samples.
|
18218096 |
2008 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The presence of somatic beta-catenin mutations in some prostate cancers implies that aberrant WNT signaling is involved in the cancer development.
|
18819930 |
2008 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although evidence of abnormal activation of the Wnt pathway in prostate cancer has been demonstrated by several groups, APC and beta-catenin mutations are infrequent.
|
18514389 |
2009 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these observations highlight the function of beta-catenin-independent Wnt signalling in the control of AR activity and provide one explanation for sFRP1 downregulation in prostate cancer.
|
19277043 |
2009 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Abnormal expression of Wnt5a and beta-catenin was observed in 27 (28%) and 49 (50%) of 98 prostate cancer cases, respectively, by immunohistochemical analyses.
|
20101234 |
2010 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Mining of publicly available human prostate cancer oligoarray datasets revealed that the expression of numerous genes (e.g., CCND1, CD44) under the control of beta-catenin transcription is down-regulated.
|
20454608 |
2010 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We selected and genotyped 13 tagged single-nucleotide polymorphisms (tSNP) to predict common variants across entire APC and CTNNB1 genes in 307 patients with clinically localized PCa who received RP and 371 unaffected controls.
|
19777185 |
2010 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, we detected the endogenous protein complex containing ICAT, AR, and β-catenin in prostate cancer cells using immunoprecipitation assays.
|
21885566 |
2011 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our studies indicated that MLK3 can induce β-catenin expression via post-translational stabilization in various cancer cells, including prostate cancer.
|
21880738 |
2011 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of Wnt signal activity through β-catenin shRNA cause a reversal of EMT induced by HIF-1α in human prostate cancer.
|
21649463 |
2011 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Heightened expression of the Trop2 intracellular domain promotes stem/progenitor self-renewal through signaling via β-catenin and is sufficient to initiate precursor lesions to prostate cancer in vivo.
|
23070813 |
2012 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Ten genes were expressed differently (false discovery rate, 0.05) in MDA prostate cancer 118b cells with downregulated β-catenin.
|
22298898 |
2012 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Particularly, the sustained activation of epidermal growth factor receptor (EGFR), hedgehog, Wnt/β-catenin, Notch, hyaluronan (HA)/CD44 and stromal cell-derived factor-1 (SDF-1)/CXC chemokine receptor 4 (CXCR4) during the epithelial-mesenchymal transition (EMT) process may provide critical functions for PC progression to locally invasive, metastatic and androgen-independent disease states and treatment resistance.
|
21607288 |
2012 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
The influence of matriptase-2 on prostate cancer in vitro: a possible role for β-catenin.
|
22858929 |
2012 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Here, we report the mechanism of EGFR expression by transcriptionally active β-catenin in GSK3β-inactivated prostate cancer cells that eventually leads to its enhanced proliferation and survival.
|
22493441 |
2012 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
β-Catenin is essential for many developmental processes and has been implicated in tumorigenesis in many tissues, including prostate cancer.
|
23300485 |
2013 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the current study, we have investigated the role of wnt/β-catenin pathway in PCa progression, skeletal metastasis, and gene expression using the dominant negative plasmid of LRP5 (DN-LRP5) and human PCa cells PC-3.
|
24403228 |
2013 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Similarly, AR79 inhibited β-catenin phosphorylation, increased nuclear β-catenin accumulation in prostate cancer and osteoblast cell lines, and increased proliferation of prostate cancer cells in vitro through β-catenin.
|
24088787 |
2013 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this study, we explore the relationship of p68 and β-Catenin in PCa to assess their potential co-operation in AR-dependent gene expression, which may be of importance in the development of castrate resistant prostate cancer (CRPCa).
|
23349811 |
2013 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Interestingly, C3 treatment resulted in decreased AR binding to target genes accompanied by decreased recruitment of an AR and β-catenin cofactor, coactivator-associated arginine methyltransferase 1 (CARM1), providing insight into the unrecognized function of β-catenin in prostate cancer.
|
24019458 |
2013 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
The reduction of miR-320 associated with increased β-catenin was also found in CD44(high) subpopulation of prostate cancer cells and clinical PCa specimens.
|
23188675 |
2013 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Finally, we demonstrated that rottlerin was able to suppress the expression of cyclin D1 and survivin, two targets of both Wnt/β-catenin and mTORC1 signaling, in prostate and breast cancer cells, and displayed remarkable anticancer activity with IC(50) values between 0.7 and 1.7 μM for prostate cancer PC-3 and DU145 cells and breast cancer MDA-MB-231 and T-47D cells.
|
24607787 |
2014 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The RNA-binding protein hnRNPA2 regulates β-catenin protein expression and is overexpressed in prostate cancer.
|
24823909 |
2014 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of β-catenin activation of the DKK1 promoter in prostate cancer.
|
23752183 |
2014 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
PBK/TOPK enhances aggressive phenotype in prostate cancer via β-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion.
|
25909225 |
2015 |